GLP-1 Drugs Cut Knee Osteoarthritis and Joint Replacement Risk by 15% in Large Taiwanese Diabetes Population

Population-based retrospective cohort study using Taiwan's National Health Insurance Database. 35,762 patients with T2DM were identified. GLP-1RA users were propensity score-matched 1:1 with non-users by sex, age, and inclusion date. Two analyses were performed: KOA development in T2DM without baseline KOA, and TKR rates in T2DM with baseline KOA. Cox proportional hazards regression estimated adjusted hazard ratios over a maximum 5-year follow-up.

Knee osteoarthritis is the most common joint disease, affecting over 250 million people worldwide. Total knee replacement — while effective — is a major surgery with significant cost, recovery time, and complication risk. If GLP-1 drugs can reduce both KOA development and the need for TKR, this represents a substantial additional benefit for the hundreds of millions of T2DM patients worldwide. The effect may be mediated through weight loss (reducing mechanical joint stress), anti-inflammatory properties, or emerging evidence that GLP-1 receptors are expressed in cartilage and may directly protect joint tissue.

This study adds joint protection to the growing list of GLP-1 drug benefits beyond glucose control — joining cardiovascular protection, kidney protection, liver disease improvement, and potential neurological benefits. The finding is particularly significant because it suggests GLP-1 drugs could reduce the burden of one of the most common and costly surgical procedures worldwide (over 1 million knee replacements annually in the US alone). It contributes to the emerging narrative that GLP-1 drugs may be among the most broadly beneficial medications ever developed.

As a retrospective observational study, it cannot establish causation — GLP-1RA users may differ from non-users in unmeasured ways despite propensity score matching. The study could not determine whether the benefit was driven by weight loss (the most likely explanation), anti-inflammatory effects, or direct joint-protective mechanisms. Specific GLP-1RA agents and doses were not differentiated. The Taiwanese population may have different obesity and OA patterns than other populations. The ICD-based diagnosis of KOA may lack precision compared to imaging or clinical assessment.